Reimbursement rate set for CareDx's AlloSure By: MarketMinute.com Stock News September 26, 2017 at 18:06 PM EDT Palmetto GBA's Molecular Diagnostics Service set the reimbursement for CareDx Inc.'s (Nasdaq: CDNA) AlloSure cfDNA-based organ transplant test diagnostic at $2,840.75. The stock price climbed 79 cents to close at $4.12. Related Stocks: Caredx Inc